ATRY: Atrys Health, S.A. - Summary | Jitta

Atrys Health, S.A.

ESP:ATRY

Price
€2.72
Loss Chance
57.9%
1.87JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
127 / 139
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (27)
Recent Business Performance (25)
Financial Strength (35)
Return to Shareholders (5)
Competitive Advantage (40)
Jitta Signs
Revenue and EarningEarning loss detected in 2025
Operating MarginDeclined
Recent Business PerformanceEarning decline 955.01% in the last quarter (yoy)
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.87
100.00%
4.64
105.67%
COMPANY DESCRIPTION
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through Diagnosis, Oncology, and Preventive Medicine segments. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; online medical imaging in the fields of radiology and cardiology; oncology treatment services, such as chemotherapy, immunotherapy, radiotherapy, and brachytherapy; second opinion and genetic counselling; and diagnostic reports and genetic tests. It also provides telemedicine services, such as teleradiology, telecardiology, teleoncology, teledermatology, teleophthalmology, and teleconsultations; prevention plans for companies, which includes training plans on occupational risk prevention; Smart Data, a technological database for healthcare; and research and development services. The company was formerly known as Althia Health, S.L. and changed its name to Atrys Health, S.A. in May 2016. Atrys Health, S.A. was incorporated in 2007 and is headquartered in Madrid, Spain.